Centro de Ciências Sociais, Saúde e Tecnologia, Universidade Federal do Maranhão, Imperatriz, MA, Brazil.
Rev Bras Ginecol Obstet. 2020 Dec;42(12):820-828. doi: 10.1055/s-0040-1719147. Epub 2020 Dec 21.
To evaluate the distribution of the main sociodemographic and clinical-pathological characteristics in women with breast cancer according to the molecular profile by immunohistochemistry.
A cross-sectional, retrospective, analytical and quantitative study was performed, with an analysis of 137 medical records from January 2015 to December 2018 of women attending the High Complexity in Oncology Unit of the city of Imperatriz, state of Maranhão, Brazil. The immunohistochemical profile of tumors based on the estrogen and progesterone receptor, Human Epidermal growth factor Receptor-type 2 (HER2) overexpression and Ki67 cell proliferation index was defined, from which six molecular subtypes were determined: luminal A, luminal B-HER2 negative, luminal B-HER2 positive, triple negative, overexpression of HER2 and inconclusive.
A total of 52.6% of the patients were postmenopausal, mean age 52.1 years old, brown (56.2%), had a schooling level < 9 years (40%), staging > IIB (52.6%) and 23.4% had metastasis. Invasive ductal carcinoma accounted for 84.7%, tumor size was 2 to 5 cm (48.9%), with lymph node involvement (56.2%), axillary lymphadenectomy in 67.2%, and mastectomy in 73.7% of the patients. The most frequent molecular subtype was the luminal B-HER2 negative (36.5%), and the luminal A subtype showed characteristics of better prognosis when compared with the others.
It was concluded that in the association of molecular subtypes with sociodemographic and clinical-pathological characteristics, there were no statistically significant results obtained, except for complementary therapy, referring to hormone therapy, and there was a high index of metastasis at diagnosis, which was a worrying factor and indicative of failures in the screening and early diagnosis of this population.
通过免疫组织化学评估乳腺癌患者根据分子特征的主要社会人口学和临床病理特征分布。
这是一项横断面、回顾性、分析性和定量研究，对 2015 年 1 月至 2018 年 12 月期间在巴西马拉尼昂州因佩拉特里斯市肿瘤高复杂度单位就诊的 137 名女性的病历进行了分析。根据雌激素和孕激素受体、人表皮生长因子受体 2（HER2）过表达和 Ki67 细胞增殖指数的肿瘤免疫组织化学特征进行定义，由此确定了六个分子亚型：管腔 A、管腔 B-HER2 阴性、管腔 B-HER2 阳性、三阴性、HER2 过表达和不确定。
共 52.6%的患者处于绝经后状态，平均年龄 52.1 岁，棕色（56.2%），受教育程度低于 9 年（40%），分期> IIB（52.6%），23.4%有转移。浸润性导管癌占 84.7%，肿瘤大小为 2 至 5cm（48.9%），淋巴结受累（56.2%），67.2%进行了腋窝淋巴结清扫，73.7%的患者进行了乳房切除术。最常见的分子亚型是管腔 B-HER2 阴性（36.5%），与其他亚型相比，管腔 A 亚型具有更好的预后特征。
在分子亚型与社会人口学和临床病理特征的关联中，除了补充治疗（即激素治疗）外，没有得出统计学上显著的结果，并且在诊断时存在较高的转移率，这是一个令人担忧的因素，表明该人群的筛查和早期诊断存在失败。
